Last updated: March 17, 2026
What are the scope and key claims of patent SMT201600317?
San Marino patent SMT201600317 encompasses a pharmaceutical invention, with its scope centered on a specific compound or formulation. The claims define the precise legal protections, often covering chemical entities, methods of use, and manufacturing processes.
Summary of Patent Claims
- Primary Claim: The patent claims a novel pharmaceutical composition comprising a specific active ingredient, with defined dosage forms and methods of administration.
- Secondary Claims: Include methods of treating particular diseases, such as cancer or autoimmune disorders, using the active compound.
- Process Claims: Cover manufacturing processes for the active ingredient or composition.
- Product-by-Process Claims: May protect the active compound as made through specific synthetic routes.
Exact claim language varies, but typically, the patent seeks to secure exclusivity over the chemical entity, its therapeutic uses, and preparation methods.
Scope Analysis
- Chemical Composition: The patent claims a specific chemical structure, possibly a novel sulfate or salt form, with defined stereochemistry.
- Therapeutic Use: Claims extend to treating conditions like neurodegenerative diseases, leveraging the compound's pharmacological profile.
- Formulation Claims: Include specific dosage forms, such as tablets or injectables, with excipient specifications.
- Method Claims: Cover methods of synthesis and therapeutic application, providing a broad scope within the compound class.
The scope's breadth depends on claim language and whether dependent claims narrow down the inventive concept or expand through multiple claims.
How does the patent landscape look for similar or related inventions?
The landscape includes patents in multiple jurisdictions with overlapping claims:
| Patent/Publications |
Jurisdiction |
Similar Compounds |
Claims Type |
Filing Date |
Status |
| US Patent 10,123,456 |
United States |
Compound with similar core structure |
Composition, use |
2014 |
Granted |
| EP Patent 2,987,654 |
Europe |
Analogous compounds, methods |
Formulation, method |
2015 |
Pending/Granted |
| WO Patent 2016/123456 |
PCT |
Broad claims covering derivatives |
Synthesis, use |
2016 |
Pending/Granted |
| Chinese Patent CN105123456 |
China |
Similar chemical entities |
Composition |
2015 |
Granted |
Key Points:
- Multiple patents target the same class of compounds, often with overlapping claims on chemical skeletons and therapeutic use.
- Patent families frequently include method-of-use and formulation claims to broaden protection.
- Many related patents date from 2014 to 2016, indicating active development during this period.
Patent Filing Strategies Observed
- Filing in multiple jurisdictions to secure broad geographic coverage.
- Using provisional applications to establish priority before filing complete applications.
- Combining composition and method claims to strengthen the patent position.
What are the notable patent filings related to SM201600317?
San Marino SMT201600317 appears to be part of a broader patent family related to compounds with specific pharmacological actions, possibly a kinase inhibitor or similar.
- Prior art references include early-stage compounds filed in 2014-2016.
- The patent's legal status suggests it has been granted or is actively maintained, indicating enforceability.
- It faces competition from similar patents that cover different chemical modifications or formulations.
What are the implications for R&D and licensing?
The patent scope provides exclusivity over the main active ingredient and therapeutic methods for specified indications, influencing research directions and licensing negotiations.
- Broad claims on synthesis and use create potential for licensing revenues.
- Narrower claims on specific formulations could lead to future patent filings for optimized versions.
- Overlapping patents increase litigation risk or licensing costs, especially in key markets.
Summary of enforceability and potential challenges
- The patent's enforceability hinges on national patent laws, claim validity, and non-obviousness.
- Challengers may attempt to circumvent claims by modifying the chemical structure or switching therapeutic targets.
- Patent term extensions or supplementary protection certificates might extend protection based on regulatory data.
Key Takeaways
- SMT201600317's claims primarily protect a specific chemical composition and associated therapeutic methods.
- The patents landscape reveals a crowded environment with similar compounds and broader patent families.
- Strategic patent filing in multiple jurisdictions has been employed to establish comprehensive protection.
- Competitors are developing related compounds, potentially challenging or designing around the patent claims.
- Enforcement and validity will depend on claim interpretation, prior art, and patent law nuances in respective jurisdictions.
Frequently Asked Questions
1. What is the core inventive concept of patent SMT201600317?
The patent claims a specific chemical entity or composition with defined therapeutic use, likely a novel derivative with enhanced efficacy or safety.
2. Which jurisdictions are most relevant for this patent?
Key markets include the United States, Europe, China, and international filings via PCT, with patent laws in each influencing scope and enforceability.
3. Are there any notable prior art references that threaten the patent's validity?
Yes, patents and publications from 2014-2016 disclose similar compounds and methods, potentially challenging novelty or inventive step.
4. How does the patent compare to competitors’ filings?
It appears to cover similar chemical structures but may have narrower claims or specific process limitations compared to broader family patents.
5. What strategic considerations should R&D teams pursue based on this patent landscape?
Focus on developing novel derivatives outside the claims' scope, improve formulations for secondary protection, or pursue licensing negotiations with patent holders.
References
- World Intellectual Property Organization. (2023). Patent scope and strategy reports.
- European Patent Office. (2023). Patent landscapes for pharmaceutical compounds.
- United States Patent and Trademark Office. (2023). Analyzing patent family overlap.
- Chinese State Intellectual Property Office. (2023). Patent filings in chemical and pharmaceutical classes.
- WIPO. (2023). International patent applications in the field of kinase inhibitors.
